Brief: Maze Therapeutics Appoints Misbah Tahir As Chief Financial Officer
U.S. STOCKS ON THE MOVE-Maze Therapeutics, UFP Technologies, Itron
Maze Therapeutics rises as brokerages initiate coverage post research quiet period
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut (updated)
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
Biotech firm Maze Therapeutics raises $140 million in US IPO (updated)
Brief: Maze Therapeutics Announces Pricing Of Upsized Initial Public Offering
Maze Therapeutics targets up to $728 mln valuation in US IPO (updated)
Maze Therapeutics targets to raise up to $133 mln in US IPO